ArticleDigestive diseases and sciences2018
Fecal Transplantation for Treatment of Clostridium Difficile Infection in Elderly and Debilitated Patients.
Article in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).The Cochrane database of systematic reviews · 2023Pooled it
- Global, regional, and national burden of Clostridioides difficile infection (1990-2021) with projections to 2051: A multimodal analysis integrating machine learning (SHAP-XGBoost) and GBD 2021 data.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Guidelines for Antibiotics Prescription in Critically Ill Patients.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Aging and Inflammation.Cold Spring Harbor perspectives in medicine · 2024Review
- Catestatin: Antimicrobial Functions and Potential Therapeutics.Pharmaceutics · 2023Review
- Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases.International journal of molecular sciences · 2022Review
- The gut microbiome as a modulator of healthy ageing.Nature reviews. Gastroenterology & hepatology · 2022Review
- Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.Journal of clinical medicine · 2022Review
- Gut Microbiota Composition Associated withPathogens (Basel, Switzerland) · 2022Review
- Fecal Microbiota Transplant in Recurrent Clostridium Difficile Infections: A Systematic Review.Cureus · 2022Review
- Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.Journal of neurogastroenterology and motility · 2022Review
- A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group.United European gastroenterology journal · 2021Article
- Gastrointestinal tract microbiota modifications in systemic sclerosis.European journal of rheumatology · 2020Review
- The situation of infection in the elderly in Spain: a multidisciplinary opinion document.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Article
- Fecal Microbiota Transplantation for RecurrentGastroenterology research · 2020Article
- Mini-Review: Human Microbiome and Rheumatic Diseases.Frontiers in cellular and infection microbiology · 2020Review
- Guidelines for Antibiotic Prescription in Intensive Care Unit.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2019Article
- Five years of fecal microbiota transplantation - an update of the Israeli experience.World journal of gastroenterology · 2018Article
- The Gut Microbiome in Multiple Sclerosis: A Potential Therapeutic Avenue.Medical sciences (Basel, Switzerland) · 2018Review
- Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis.Annals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFecal microbiota transplantation (FMT) is a new technique recently introduced to treat recurrent Clostridium difficile infection (CDI). Little is known about the efficacy and risks of FMT in elderly and ill patients.
aimTo investigate FMT efficacy in ill and elderly patients compared to conventional treatment.
methodsThe study comprised two groups of patients between 2012 and 2016 with recurrent CDI at two medical centers in Israel. The study group received FMT and the controls conventional therapy. The primary end points were CDI recurrence, length of hospitalization, and short-term survival.
resultsThirty-four patients altogether, (21 females, mean age 82 years) participated, 11 received FMT and 23 controls. Demographics and clinical characteristics were similar between the two groups. Comorbidity indexes, i.e., Charlson index was high in both groups. In the FMT group, 10/11 (90%) patients showed clinical improvement 3 days after initiating treatment compared to 9/23 (39%) in the control group, p = 0.02. Survival at 2 months did not differ between the groups (FMT 54%, Control 50%, p = 0.816), but mean survival in the FMT group was higher than in the control (12 vs. 4 months, respectively, p = 0.015). Two significant adverse events from the FMT group included suspected aspirations, both occurring during gastroscopy route of administration.
conclusionsFMT is effective for elderly and very ill patients. Safety is a concern, but is rare even in patients with much comorbidity. Colonoscopy may be the preferred route of FMT infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.